Asia Pacific Automated and Closed Cell Therapy Processing Systems Market Size, Share, and COVID-19 Impact Analysis, By Workflow (Separation, Expansion, Apheresis, Fill- Finish, and Others), By Type (Stem Cell Therapy and Non Stem Cell Therapy), and Asia Pacific Automated and Closed Cell Therapy Processing Systems Market Insights, Industry Trend, Forecasts to 2035

Asia Pacific Automated and Closed Cell Therapy Processing Systems Market Insights Forecasts to 2035

• The Asia Pacific Automated and Closed Cell Therapy Processing Systems Market Was Estimated at USD 269.8 Million in 2024.
• The Market Size is Growing at a CAGR of 20.74% between 2025 and 2035.
• The Asia Pacific Automated and Closed Cell Therapy Processing Systems market is Anticipated to Reach USD 2144.5 Million by 2035.

According to a research report published by Spherical Insights & Consulting, the Asia Pacific automated and closed cell therapy processing systems market is anticipated to Hold USD 2144.5 Million by 2035, growing at a CAGR of 20.74% from 2025 to 2035. The Asia Pacific market is poised for growth in cell & gene therapy automated & closed cell therapy processing system areas driven largely by the growth of cell and gene therapy research across the Asia Pacific region, as well as increased clinical trial activity, increased biopharma investments in C&GTs, the growing demand for easily contaminated-free processing methods and the growing use of automation for both scaling, and improving the quality and/or quantity of C&GT manufacturing.

Market Overview

The Asia-Pacific automated and closed cell therapy processing systems market represents a growing segment of industry-focused on providing advanced technologies for the production of cell therapies using a completely automated and enclosed manufacturing process that will provide a higher degree of sterility and consistency from batch to batch as well as allow for scalability. This market is rapidly expanding due, in large part, to an increase in investment by many countries throughout the Asia-Pacific region, particularly China, Japan, South Korea, and India in regenerative medicine, stem cell research, and ATMP development. The increasing popularity of CAR-T therapies, the increased number of clinical trials, and the increasing desire to minimize manual error are driving demand for the use of automated and closed processing systems. Biopharmaceutical companies are utilizing these systems to create products that are of a higher quality, have lower risks associated with contamination, and provide a greater degree of reproducibility. The combination of supportive government policies, an expanding biotechnology infrastructure, and increasing levels of outsourcing to contract development and manufacturing organisations (CDMOs) will continue to create opportunities for the development of new automated and closed cell therapy processing systems in the Asia-Pacific Region.

Report Coverage

This research report categorizes the market for the Asia Pacific automated and closed cell therapy processing systems market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific automated and closed cell therapy processing systems market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific automated and closed cell therapy processing systems market.

Driving Factors

The expansion of the Asia Pacific automated and closed cell therapy processing systems market is exhibiting a trend of strong growth led largely by the rising number of cell and gene therapy products being developed, the increasing number of clinical trials taking place in this region, and increasing investment in regenerative medicine within China, Japan, South Korea and India. The pressing need to limit potential sources of contamination as well as to create maximum process reproducibility is driving the adoption of automated and closed cell therapy processing [device/process] systems. Supportive government programs, increasing reliance on CDMO providers, and expanded availability of Biotech infrastructure are all contributing to the growing demand for automation within the Asia Pacific region. The trend toward achieving scalable, reproducible manufacturing processes enables development of more efficient automated manufacturing platforms.

Restraining Factors

Obstacles in the Asia Pacific automated and closed cell therapy processing systems market may include high prices of equipment, fewer qualified individuals available to operate these advanced technologies, and stringent requirements placed on manufacturers by regulatory agencies for advanced therapies. There are also many areas in which emerging markets lack sufficient infrastructure for the manufacture of cell therapy products. Finally, difficulties with the ability to grow and distribute personalized cell therapy products have hindered the wider use of cell therapies.

Market Segmentation

The Asia Pacific automated and closed cell therapy processing systems market share is classified into Workflow and Type.

• The separation segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific automated and closed cell therapy processing systems market is segmented by workflow into separation, expansion, apheresis, fill- finish, and others. Among these, the separation segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Separation held a significant share in 2024 because it is one of the most critical and frequently performed steps in cell therapy manufacturing, requiring high precision and sterility.

• The stem cell therapy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific automated and closed cell therapy processing systems market is segmented by type into stem cell therapy and non-stem cell therapy. Among these, the stem cell therapy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Stem Cell Therapy held a significant share in 2024 because stem cell research and clinical applications especially MSC and iPSC therapies are highly active across China, Japan, South Korea, and India.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific automated and closed cell therapy processing systems market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Cellares
• Biospherix
• Cytiva
• Miltenyi Biotec
• Terumo Corp
• Sartorius AG
• Thermo Fisher Scientific Inc
• ThermoGenesis Holdings Inc

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Europe, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific automated and closed cell therapy processing systems market based on the following segments:

Asia Pacific Automated and Closed Cell Therapy Processing Systems Market, By Workflow

• Separation
• Expansion
• Apheresis
• Fill- Finish
• Others

Asia Pacific Automated and Closed Cell Therapy Processing Systems Market, By Type

• Stem Cell Therapy
• Non Stem Cell Therapy